Stryker Co. (NYSE:SYK) Stock Position Lessened by Armor Investment Advisors LLC

Armor Investment Advisors LLC decreased its holdings in Stryker Co. (NYSE:SYK) by 6.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 710 shares of the medical technology company’s stock after selling 45 shares during the quarter. Armor Investment Advisors LLC’s holdings in Stryker were worth $256,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Ritholtz Wealth Management boosted its stake in Stryker by 6.3% during the third quarter. Ritholtz Wealth Management now owns 5,140 shares of the medical technology company’s stock valued at $1,857,000 after buying an additional 306 shares in the last quarter. Retirement Planning Group LLC bought a new position in Stryker during the third quarter valued at about $249,000. Exchange Traded Concepts LLC boosted its stake in Stryker by 1.9% during the third quarter. Exchange Traded Concepts LLC now owns 5,261 shares of the medical technology company’s stock valued at $1,901,000 after buying an additional 96 shares in the last quarter. Koshinski Asset Management Inc. boosted its stake in Stryker by 4.0% during the third quarter. Koshinski Asset Management Inc. now owns 2,403 shares of the medical technology company’s stock valued at $868,000 after buying an additional 92 shares in the last quarter. Finally, McGlone Suttner Wealth Management Inc. bought a new position in Stryker during the third quarter valued at about $295,000. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on SYK. Wells Fargo & Company raised their target price on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Royal Bank of Canada upped their target price on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Canaccord Genuity Group upped their target price on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. upped their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $420.68.

Stryker Stock Up 0.2 %

Shares of Stryker stock opened at $392.15 on Tuesday. The firm has a market cap of $149.50 billion, a price-to-earnings ratio of 50.53, a P/E/G ratio of 2.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The stock has a 50-day simple moving average of $377.23 and a 200-day simple moving average of $365.14.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business posted $3.46 EPS. On average, equities research analysts expect that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.